A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris

Trial Profile

A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs XEN 801 (Primary)
  • Indications Acne
  • Focus Therapeutic Use
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 24 Mar 2017 Results published in the Xenon Pharmaceuticals Media Release
    • 24 Mar 2017 Primary endpoint has not been met. (Change from Baseline in acne lesion count), as reported in a Xenon Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top